- Home
- EML vs ANVS Comparison
EML vs ANVS Comparison
Compare EML & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EML | ANVS |
|---|---|---|
| Founded | 1858 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.2M | 111.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EML | ANVS |
|---|---|---|
| Price | $20.19 | $3.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 11.2K | ★ 1.4M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $258,121,226.00 | N/A |
| Revenue This Year | $1.56 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $19.16 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.49 | $1.11 |
| 52 Week High | $30.72 | $5.60 |
Technical Indicators
Market Signals| Indicator | EML | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 48.47 |
| Support Level | $19.28 | $3.58 |
| Resistance Level | $20.86 | $4.05 |
| Average True Range (ATR) | 0.63 | 0.39 |
| MACD | 0.12 | -0.17 |
| Stochastic Oscillator | 67.16 | 14.71 |
Price Performance
Historical ComparisonAbout EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.